Compare KTB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTB | IOVA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.1B |
| IPO Year | 2018 | 2008 |
| Metric | KTB | IOVA |
|---|---|---|
| Price | $67.24 | $4.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $99.67 | $9.11 |
| AVG Volume (30 Days) | 945.5K | ★ 18.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $2,097,839,000.00 | N/A |
| Revenue This Year | $10.42 | $49.14 |
| Revenue Next Year | $3.62 | $51.69 |
| P/E Ratio | $16.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.00 | $1.64 |
| 52 Week High | $87.00 | $5.63 |
| Indicator | KTB | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 54.36 |
| Support Level | $63.04 | $1.99 |
| Resistance Level | $72.31 | $4.34 |
| Average True Range (ATR) | 3.28 | 0.47 |
| MACD | -0.82 | -0.05 |
| Stochastic Oscillator | 28.15 | 24.18 |
Kontoor Brands Inc is a lifestyle apparel company. It designs, manufactures, procures, sells, and licenses apparel, footwear, and accessories, mainly under the brand names Wrangler, Lee, Helly Hansen, and a few other brands. The company also licenses the use of its brands in certain regions. Its products are sold through wholesale and direct-to-consumer channels in the United States (its key revenue-generating market) and internationally, mainly in Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Non-U.S. Americas regions. The company's three reportable segments are Wrangler, Lee, and Helly Hansen. The majority of its revenue is generated from the Wrangler segment, which offers denim, apparel, footwear, and accessories through Wrangler and various sub-brands.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.